scholarly journals The prognostic value of age for invasive lobular breast cancer depending on estrogen receptor and progesterone receptor-defined subtypes: A NCDB analysis

Oncotarget ◽  
2015 ◽  
Vol 7 (5) ◽  
pp. 6063-6073 ◽  
Author(s):  
Jieqiong Liu ◽  
Kai Chen ◽  
Kai Mao ◽  
Fengxi Su ◽  
Qiang Liu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Progesterone Receptor ◽  
Prognostic Value ◽  
Lobular Breast Cancer ◽  
Invasive Lobular Breast Cancer

scholarly journals Prognostic Value of MammaPrint® in Invasive Lobular Breast Cancer

2016 ◽  
Vol 11 ◽  
pp. BMI.S38435 ◽  
Author(s):  
Inès J. Beumer ◽  
Marion Persoon ◽  
Anke Witteveen ◽  
Christa Dreezen ◽  
Suet-Feung Chin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Cancer Patients ◽  
Prognostic Value ◽  
Early Stage ◽  
Breast Cancer Patients ◽  
Lobular Breast Cancer ◽  
Node Negative ◽  
Study Population ◽  
Invasive Lobular Breast Cancer

Background MammaPrint® is a microarray-based gene expression test cleared by the US Food and Drug Administration to assess recurrence risk in early-stage breast cancer, aimed to guide physicians in making neoadjuvant and adjuvant treatment decisions. The increase in the incidence of invasive lobular carcinomas (ILCs) over the past decades and the modest representation of ILC in the MammaPrint development data set calls for a stratified survival analysis dedicated to this specific subgroup. Study Aim The current study aimed to validate the prognostic value of the MammaPrint test for breast cancer patients with early-stage ILCs. Materials and Methods Univariate and multivariate survival associations for overall survival (OS), distant metastasis-free interval (DMFI), and distant metastasis-free survival (DMFS) were studied in a study population of 217 early-stage ILC breast cancer patients from five different clinical studies. Results and Discussion A significant association between MammaPrint High Risk and poor clinical outcome was shown for OS, DMFI, and DMFS. A subanalysis was performed on the lymph node-negative study population. In the lymph node-negative study population, we report an up to 11 times higher change in the diagnosis of an event in the MammaPrint High Risk group. For DMFI, the reported hazard ratio is 11.1 (95% confidence interval = 2.3–53.0). Conclusion Study results validate MammaPrint as an independent factor for breast cancer patients with early-stage invasive lobular breast cancer. Hazard ratios up to 11 in multivariate analyses emphasize the independent value of MammaPrint, specifically in lymph node-negative ILC breast cancers.

scholarly journals Prognostic Value of EndoPredict in Women with Hormone Receptor–Positive, HER2-Negative Invasive Lobular Breast Cancer

2020 ◽  
Vol 26 (17) ◽  
pp. 4682-4687 ◽  
Author(s):  
Ivana Sestak ◽  
Martin Filipits ◽  
Richard Buus ◽  
Margaretha Rudas ◽  
Marija Balic ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Hormone Receptor ◽  
Prognostic Value ◽  
Lobular Breast Cancer ◽  
Hormone Receptor Positive ◽  
Invasive Lobular Breast Cancer

scholarly journals Prognostic value of estrogen receptor α and progesterone receptor conversion in distant breast cancer metastases

Cancer ◽  
2012 ◽  
Vol 118 (20) ◽  
pp. 4929-4935 ◽  
Author(s):  
Laurien D. C. Hoefnagel ◽  
Cathy B. Moelans ◽  
S. L. Meijer ◽  
Henk-Jan van Slooten ◽  
Pieter Wesseling ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Progesterone Receptor ◽  
Prognostic Value ◽  
Estrogen Receptor Α ◽  
Breast Cancer Metastases ◽  
Cancer Metastases ◽  
Receptor Conversion

scholarly journals Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor‐Positive, HER‐2 Negative Breast Cancer

2018 ◽  
Vol 24 (2) ◽  
pp. 165-171 ◽  
Author(s):  
Kathleen Van Asten ◽  
Laurence Slembrouck ◽  
Siel Olbrecht ◽  
Lynn Jongen ◽  
Olivier Brouckaert ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Progesterone Receptor ◽  
Prognostic Value ◽  
Estrogen Receptor Positive ◽  
Her 2

Progesterone receptor status and tumor grade predict the 21-gene recurrence score of invasive lobular breast cancer

2019 ◽  
Vol 13 (12) ◽  
pp. 1005-1012 ◽  
Author(s):  
San-Gang Wu ◽  
Wen-Wen Zhang ◽  
Jun Wang ◽  
Chen-Lu Lian ◽  
Jia-Yuan Sun ◽  
...  
Keyword(s):  
High Risk ◽  
Progesterone Receptor ◽  
Lobular Carcinoma ◽  
Recurrence Score ◽  
Tumor Grade ◽  
Lobular Breast Cancer ◽  
Well Differentiated ◽  
Invasive Lobular Breast Cancer ◽  
Clinicopathological Variables ◽  
High Risk Cohort

Aim: To assess the association between established clinicopathological variables and the 21-gene recurrence score (RS) stratification of invasive lobular carcinoma (ILC) of the breast. Materials & methods: We identified 9030 ILC patients from the Surveillance, Epidemiology and End Results database. Results: Older age, higher grade tumor and progesterone receptor (PR)-negative disease were independent predictors of high-risk RS stratification. Among patients with PR-positive tumors, 3, 6 and 15% with well-differentiated (G1), moderately-differentiated (G2) and poorly and/or undifferentiated (G3) disease were in the high-risk cohort, respectively. In patients with PR-negative tumors: 16, 24 and 41% of patients with G1, G2 and G3 disease were in the high-risk cohort, respectively. Conclusion: The 21-gene RS testing may not be necessary for patients with PR+/G1–2 ILC.

Sign in / Sign up

Export Citation Format

Share Document